12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pradaxa regulatory update

Boehringer Ingelheim said the U.S. label for Pradaxa dabigatran etexilate was updated to include data from the Phase III RE-LY trial in non-valvular atrial fibrillation (AF) patients showing that 150 mg Pradaxa was superior to warfarin in reducing...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >